retatrutide benefits clinical trials This weight-loss drug hasn't been approved by the FDA. Doctors are prescribing it anyway Retatrutide—A Game Changer in Obesity

Canadian regulations permit the sale of research peptides when properly labeled and marketed for research purposes only

Approximately 22% of healthcare institutions are exploring GLP-1 therapies for neurodegenerative conditions, reflecting growing interest in this application

Survodutide (BI 456906) is a GLP-1R/GCGR dual agonist developed by Boehringer Ingelheim, with outcomes of a phase 2 trial in MASLD and a phase 1 trial in cirrhosis published almost simultaneously with tirzepatide

Reconstituting only enough for four weeks at a time and keeping the remainder as lyophilized powder is the optimal approach

SLM+ (Berberine Complex & Banaba Leaf): Regulates blood sugar, enhances fat metabolism, and optimizes overall metabolic function